Skip to main content
Erschienen in: World Journal of Urology 1/2011

01.02.2011 | Topic Paper

Long-term urinary adverse effects of pelvic radiotherapy

verfasst von: Sean P. Elliott, Bahaa S. Malaeb

Erschienen in: World Journal of Urology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective

Radiation for tumors arising in the pelvis has been utilized for over a 100 years. Adverse effects (AEs) of radiotherapy (RT) continue to accumulate with time and are reported to show decades after treatment. The benefit of RT for pelvic tumors is well described as is their acute AEs. Late AEs are less well described. The burden of treatment for the late AEs is large given the high utilization of RT.

Review

For prostate cancer, 37% of patients will receive radiation during the first 6 months after diagnosis. Low-and high-grade AEs are reported to occur in 20–43 and 5–13%, respectively, with a median follow-up of ~60 months. For bladder cancer, the grade 2 and grade 3 late AEs occur in 18–27 and 6–17% with a median follow-up of 29–76 months. For cervical cancer, the risk of low-grade AEs following radiation can be as high as 28%. High-grade AEs occur in about 8% at 3 years and 14.4% at 20 years or ~0.34% per year. Radiation AEs appear to be less common or at least less well studied after radiation for rectal and endometrial cancers.

Conclusion

Properly delineating the rate of long-term AEs after pelvic RT is instrumental to counseling patients about their options for cancer treatment. Further studies are needed that are powered to specifically evaluate long-term AEs.
Literatur
1.
Zurück zum Zitat Cancer Facts & Figures 2009 (2009) American Cancer Society, Atlanta Cancer Facts & Figures 2009 (2009) American Cancer Society, Atlanta
2.
Zurück zum Zitat Elliott SP, Jarosek SA, Virnig BA. Unpublished analysis of SEER public use file 1992–2006 Elliott SP, Jarosek SA, Virnig BA. Unpublished analysis of SEER public use file 1992–2006
3.
Zurück zum Zitat Crew JP, Jephcott CR, Reynard JM (2001) Radiation-induced haemorrhagic cystitis. Eur Urol 40:111–123CrossRefPubMed Crew JP, Jephcott CR, Reynard JM (2001) Radiation-induced haemorrhagic cystitis. Eur Urol 40:111–123CrossRefPubMed
4.
Zurück zum Zitat deVries CR, Freiha FS (1990) Hemorrhagic cystitis: a review. J Urol 143:1–9PubMed deVries CR, Freiha FS (1990) Hemorrhagic cystitis: a review. J Urol 143:1–9PubMed
5.
Zurück zum Zitat Elliott SP, Meng MV, Elkin EP, McAninch JW, Duchane J, Carroll PR (2007) Incidence of urethral stricture after primary treatment for prostate cancer: data from CaPSURE. J Urol 178:529–534 (discussion 34)CrossRefPubMed Elliott SP, Meng MV, Elkin EP, McAninch JW, Duchane J, Carroll PR (2007) Incidence of urethral stricture after primary treatment for prostate cancer: data from CaPSURE. J Urol 178:529–534 (discussion 34)CrossRefPubMed
6.
Zurück zum Zitat Fujikawa K, Miyamoto T, Ihara Y, Matsui Y, Takeuchi H (2001) High incidence of severe urologic complications following radiotherapy for cervical cancer in Japanese women. Gynecol Oncol 80:21–23CrossRefPubMed Fujikawa K, Miyamoto T, Ihara Y, Matsui Y, Takeuchi H (2001) High incidence of severe urologic complications following radiotherapy for cervical cancer in Japanese women. Gynecol Oncol 80:21–23CrossRefPubMed
7.
Zurück zum Zitat Gellrich J, Hakenberg OW, Oehlschlager S, Wirth MP (2003) Manifestation, latency and management of late urological complications after curative radiotherapy for cervical carcinoma. Onkologie 26:334–340CrossRefPubMed Gellrich J, Hakenberg OW, Oehlschlager S, Wirth MP (2003) Manifestation, latency and management of late urological complications after curative radiotherapy for cervical carcinoma. Onkologie 26:334–340CrossRefPubMed
8.
Zurück zum Zitat Common Terminology Criteria for Adverse Events, Version 4.0. In: National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. In: National Cancer Institute
9.
Zurück zum Zitat Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346CrossRefPubMed Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346CrossRefPubMed
10.
Zurück zum Zitat Pavy JJ, Denekamp J, Letschert J et al (1995) Late effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys 31:1042–1049 Pavy JJ, Denekamp J, Letschert J et al (1995) Late effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys 31:1042–1049
11.
Zurück zum Zitat Zelefsky MJ, Levin EJ, Hunt M et al (2008) Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70:1124–1129CrossRefPubMed Zelefsky MJ, Levin EJ, Hunt M et al (2008) Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70:1124–1129CrossRefPubMed
12.
Zurück zum Zitat Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases, improves survival: long-term followup of a randomized clinical trial. J Urol 181(3):956–962CrossRefPubMed Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases, improves survival: long-term followup of a randomized clinical trial. J Urol 181(3):956–962CrossRefPubMed
13.
Zurück zum Zitat Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148:435–448PubMed Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148:435–448PubMed
14.
Zurück zum Zitat Pickett B, Kurhanewicz J, Pouliot J et al (2006) Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys 65:65–72CrossRefPubMed Pickett B, Kurhanewicz J, Pouliot J et al (2006) Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys 65:65–72CrossRefPubMed
15.
Zurück zum Zitat Potters L, Morgenstern C, Calugaru E et al (2005) 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173:1562–1566CrossRefPubMed Potters L, Morgenstern C, Calugaru E et al (2005) 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173:1562–1566CrossRefPubMed
16.
Zurück zum Zitat Zelefsky MJ, Wallner KE, Ling CC et al (1999) Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 17:517–522PubMed Zelefsky MJ, Wallner KE, Ling CC et al (1999) Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 17:517–522PubMed
17.
Zurück zum Zitat Zelefsky MJ, Cowen D, Fuks Z et al (1999) Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85(11):2460–2468CrossRefPubMed Zelefsky MJ, Cowen D, Fuks Z et al (1999) Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85(11):2460–2468CrossRefPubMed
18.
Zurück zum Zitat Zietman AL, DeSilvio ML, Slater JD et al (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294(10):1233–1239CrossRefPubMed Zietman AL, DeSilvio ML, Slater JD et al (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294(10):1233–1239CrossRefPubMed
19.
Zurück zum Zitat Lawton CA, Won M, Pilepich MV et al (1991) Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21:935–939CrossRefPubMed Lawton CA, Won M, Pilepich MV et al (1991) Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21:935–939CrossRefPubMed
20.
Zurück zum Zitat Peeters ST, Heemsbergen WD, Koper PC et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990–1996CrossRefPubMed Peeters ST, Heemsbergen WD, Koper PC et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990–1996CrossRefPubMed
21.
Zurück zum Zitat Peeters ST, Heemsbergen WD, van Putten WL et al (2005) Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61:1019–1034CrossRefPubMed Peeters ST, Heemsbergen WD, van Putten WL et al (2005) Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61:1019–1034CrossRefPubMed
22.
Zurück zum Zitat Chong KT, Hampson NB, Corman JM (2005) Early hyperbaric oxygen therapy improves outcome for radiation-induced hemorrhagic cystitis. Urology 65(4):649–653CrossRefPubMed Chong KT, Hampson NB, Corman JM (2005) Early hyperbaric oxygen therapy improves outcome for radiation-induced hemorrhagic cystitis. Urology 65(4):649–653CrossRefPubMed
23.
Zurück zum Zitat Zelefsky MJ, Yamada Y, Cohen GN et al (2007) Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 67:65–70CrossRefPubMed Zelefsky MJ, Yamada Y, Cohen GN et al (2007) Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 67:65–70CrossRefPubMed
24.
Zurück zum Zitat Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE (2000) Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47:1261–1266CrossRefPubMed Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE (2000) Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47:1261–1266CrossRefPubMed
25.
Zurück zum Zitat Chen AB, D’Amico AV, Neville BA, Earle CC (2006) Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 24:5298–5304CrossRefPubMed Chen AB, D’Amico AV, Neville BA, Earle CC (2006) Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 24:5298–5304CrossRefPubMed
26.
Zurück zum Zitat Anderson JF, Swanson DA, Levy LB et al (2009) Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson cancer center experience. Urology 74:601–605CrossRefPubMed Anderson JF, Swanson DA, Levy LB et al (2009) Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson cancer center experience. Urology 74:601–605CrossRefPubMed
27.
Zurück zum Zitat Sarosdy MF (2004) Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Cancer 101:754–760CrossRefPubMed Sarosdy MF (2004) Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Cancer 101:754–760CrossRefPubMed
28.
Zurück zum Zitat Hussain SA, Stocken DD, Peake DR et al (2004) Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 90:2106–2111PubMed Hussain SA, Stocken DD, Peake DR et al (2004) Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 90:2106–2111PubMed
29.
Zurück zum Zitat Efstathiou JA, Bae K, Shipley WU et al (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 27:4055–4061CrossRefPubMed Efstathiou JA, Bae K, Shipley WU et al (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 27:4055–4061CrossRefPubMed
30.
Zurück zum Zitat Hagan MP, Winter KA, Kaufman DS et al (2003) RTOG 97–06: Initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57:665–672CrossRefPubMed Hagan MP, Winter KA, Kaufman DS et al (2003) RTOG 97–06: Initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57:665–672CrossRefPubMed
31.
Zurück zum Zitat Milosevic M, Gospodarowicz M, Zietman A et al (2007) Radiotherapy for bladder cancer. Urology 69:80–92CrossRefPubMed Milosevic M, Gospodarowicz M, Zietman A et al (2007) Radiotherapy for bladder cancer. Urology 69:80–92CrossRefPubMed
32.
Zurück zum Zitat Gogna NK, Matthews JH, Turner SL et al (2006) Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol 81:9–17CrossRefPubMed Gogna NK, Matthews JH, Turner SL et al (2006) Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol 81:9–17CrossRefPubMed
33.
Zurück zum Zitat Fokdal L, Hoyer M, Meldgaard P, von der Maase H (2004) Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. Radiother Oncol 72:139–145CrossRefPubMed Fokdal L, Hoyer M, Meldgaard P, von der Maase H (2004) Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. Radiother Oncol 72:139–145CrossRefPubMed
34.
Zurück zum Zitat Henningsohn L, Wijkstrom H, Dickman PW, Bergmark K, Steineck G (2002) Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 62:215–225CrossRefPubMed Henningsohn L, Wijkstrom H, Dickman PW, Bergmark K, Steineck G (2002) Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 62:215–225CrossRefPubMed
35.
Zurück zum Zitat Majewski W, Tarnawski R (2009) Acute and late toxicity in radical radiotherapy for bladder cancer. Clin Oncol (R Coll Radiol) 21:598–609 Majewski W, Tarnawski R (2009) Acute and late toxicity in radical radiotherapy for bladder cancer. Clin Oncol (R Coll Radiol) 21:598–609
36.
Zurück zum Zitat Hoskin PJ, Rojas AM, Phillips H, Saunders MI (2005) Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide. Cancer 103:2287–2297CrossRefPubMed Hoskin PJ, Rojas AM, Phillips H, Saunders MI (2005) Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide. Cancer 103:2287–2297CrossRefPubMed
37.
Zurück zum Zitat Cowan RA, McBain CA, Ryder WD et al (2004) Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 59:197–207CrossRefPubMed Cowan RA, McBain CA, Ryder WD et al (2004) Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 59:197–207CrossRefPubMed
38.
Zurück zum Zitat Kaufman DS, Winter KA, Shipley WU et al (2009) Phase I-II RTOG study (99–06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 73:833–837CrossRefPubMed Kaufman DS, Winter KA, Shipley WU et al (2009) Phase I-II RTOG study (99–06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 73:833–837CrossRefPubMed
39.
Zurück zum Zitat Duncan W, Quilty PM (1986) The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 7:299–310CrossRefPubMed Duncan W, Quilty PM (1986) The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 7:299–310CrossRefPubMed
40.
Zurück zum Zitat Pos FJ, Horenblas S, Lebesque J et al (2004) Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer. Int J Radiat Oncol Biol Phys 59:696–705CrossRefPubMed Pos FJ, Horenblas S, Lebesque J et al (2004) Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer. Int J Radiat Oncol Biol Phys 59:696–705CrossRefPubMed
42.
Zurück zum Zitat Martling A, Holm T, Johansson H, Rutqvist LE, Cedermark B (2001) The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer 92:896–902CrossRefPubMed Martling A, Holm T, Johansson H, Rutqvist LE, Cedermark B (2001) The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer 92:896–902CrossRefPubMed
43.
Zurück zum Zitat Improved survival with preoperative radiotherapy in resectable rectal cancer (1997) Swedish rectal cancer trial. N Engl J Med 336:980–987CrossRef Improved survival with preoperative radiotherapy in resectable rectal cancer (1997) Swedish rectal cancer trial. N Engl J Med 336:980–987CrossRef
44.
Zurück zum Zitat Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740CrossRefPubMed Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740CrossRefPubMed
45.
Zurück zum Zitat McIntyre JF, Eifel PJ, Levenback C, Oswald MJ (1995) Ureteral stricture as a late complication of radiotherapy for stage IB carcinoma of the uterine cervix. Cancer 75:836–843CrossRefPubMed McIntyre JF, Eifel PJ, Levenback C, Oswald MJ (1995) Ureteral stricture as a late complication of radiotherapy for stage IB carcinoma of the uterine cervix. Cancer 75:836–843CrossRefPubMed
46.
Zurück zum Zitat Takeshi K, Katsuyuki K, Yoshiaki T et al (1998) Definitive radiotherapy combined with high-dose-rate brachytherapy for Stage III carcinoma of the uterine cervix: retrospective analysis of prognostic factors concerning patient characteristics and treatment parameters. Int J Radiat Oncol Biol Phys 41:319–327CrossRefPubMed Takeshi K, Katsuyuki K, Yoshiaki T et al (1998) Definitive radiotherapy combined with high-dose-rate brachytherapy for Stage III carcinoma of the uterine cervix: retrospective analysis of prognostic factors concerning patient characteristics and treatment parameters. Int J Radiat Oncol Biol Phys 41:319–327CrossRefPubMed
47.
Zurück zum Zitat Eifel PJ, Levenback C, Wharton JT, Oswald MJ (1995) Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 32:1289–1300CrossRefPubMed Eifel PJ, Levenback C, Wharton JT, Oswald MJ (1995) Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 32:1289–1300CrossRefPubMed
48.
Zurück zum Zitat Lorvidhaya V, Tonusin A, Changwiwit W et al (2000) High-dose-rate afterloading brachytherapy in carcinoma of the cervix: an experience of 1992 patients. Int J Radiat Oncol Biol Phys 46:1185–1191CrossRefPubMed Lorvidhaya V, Tonusin A, Changwiwit W et al (2000) High-dose-rate afterloading brachytherapy in carcinoma of the cervix: an experience of 1992 patients. Int J Radiat Oncol Biol Phys 46:1185–1191CrossRefPubMed
49.
Zurück zum Zitat Kapp KS, Stuecklschweiger GF, Kapp DS, Poschauko J, Pickel H, Hackl A (1997) Carcinoma of the cervix: analysis of complications after primary external beam radiation and Ir-192 HDR brachytherapy. Radiother Oncol 42:143–153CrossRefPubMed Kapp KS, Stuecklschweiger GF, Kapp DS, Poschauko J, Pickel H, Hackl A (1997) Carcinoma of the cervix: analysis of complications after primary external beam radiation and Ir-192 HDR brachytherapy. Radiother Oncol 42:143–153CrossRefPubMed
50.
Zurück zum Zitat Green JA, Kirwan JM, Tierney JF et al (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358:781–786CrossRefPubMed Green JA, Kirwan JM, Tierney JF et al (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358:781–786CrossRefPubMed
51.
Zurück zum Zitat Nishimura T, Suzuki K, Iijima M et al (2000) Spontaneous rupture of bladder diverticulum after postoperative radiotherapy for carcinoma of the uterine cervix: a case report. Radiat Med 18:261–265PubMed Nishimura T, Suzuki K, Iijima M et al (2000) Spontaneous rupture of bladder diverticulum after postoperative radiotherapy for carcinoma of the uterine cervix: a case report. Radiat Med 18:261–265PubMed
52.
Zurück zum Zitat Small W Jr, Du Bois A, Bhatnagar S et al (2009) Practice patterns of radiotherapy in endometrial cancer among member groups of the gynecologic cancer intergroup. Int J Gynecol Cancer 19:395–399CrossRefPubMed Small W Jr, Du Bois A, Bhatnagar S et al (2009) Practice patterns of radiotherapy in endometrial cancer among member groups of the gynecologic cancer intergroup. Int J Gynecol Cancer 19:395–399CrossRefPubMed
53.
Zurück zum Zitat Creutzberg CL, van Putten WL, Koper PC et al (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 355:1404–1411CrossRefPubMed Creutzberg CL, van Putten WL, Koper PC et al (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 355:1404–1411CrossRefPubMed
54.
Zurück zum Zitat Keys HM, Roberts JA, Brunetto VL et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744–751CrossRefPubMed Keys HM, Roberts JA, Brunetto VL et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744–751CrossRefPubMed
55.
Zurück zum Zitat Kucera H, Vavra N, Weghaupt K (1990) Benefit of external irradiation in pathologic stage I endometrial carcinoma: a prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecol Oncol 38:99–104CrossRefPubMed Kucera H, Vavra N, Weghaupt K (1990) Benefit of external irradiation in pathologic stage I endometrial carcinoma: a prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecol Oncol 38:99–104CrossRefPubMed
56.
Zurück zum Zitat Irwin C, Levin W, Fyles A, Pintilie M, Manchul L, Kirkbride P (1998) The role of adjuvant radiotherapy in carcinoma of the endometrium-results in 550 patients with pathologic stage I disease. Gynecol Oncol 70:247–254CrossRefPubMed Irwin C, Levin W, Fyles A, Pintilie M, Manchul L, Kirkbride P (1998) The role of adjuvant radiotherapy in carcinoma of the endometrium-results in 550 patients with pathologic stage I disease. Gynecol Oncol 70:247–254CrossRefPubMed
57.
Zurück zum Zitat Nguyen TV, Petereit DG (1998) High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer. Gynecol Oncol 71:196–203CrossRefPubMed Nguyen TV, Petereit DG (1998) High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer. Gynecol Oncol 71:196–203CrossRefPubMed
Metadaten
Titel
Long-term urinary adverse effects of pelvic radiotherapy
verfasst von
Sean P. Elliott
Bahaa S. Malaeb
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 1/2011
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-010-0603-x

Weitere Artikel der Ausgabe 1/2011

World Journal of Urology 1/2011 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.